Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

ACE2-cytomimetic particles restrict SARS-Cov-2 spike protein binding to cellular targets

Biotechnology Reports(2021)10.1016/j.btre.2021.e00681Source: DataRank Database

ACE2-cytomimetic particles restrict SARS-Cov-2 spike protein binding to cellular targets is a research paper published in Biotechnology Reports (2021). On theSindex it has a DataRank of 0. It has been cited 5 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access5 citations

Download PDF

Cite:

Linked data & code

pdb

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (3 grants)OA: goldTopics (10)IDs (PubMed, PMC)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (2)

Daniel Pelaez ORCID,Thomas A. Strong ORCID

Live enrichment

PubMed:34611521 PMC:PMC8482554

National Institutes of Health

Grant: P30EY014801

National Institutes of Health

Grant: 5P30EY014801-03

Miami Center for Vision Research

Research to Prevent Blindness

goldLicense: CC BY NC ND

publisherhttps://api.elsevier.com/content/article/PII:S2215017X21000977?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S2215017X21000977?httpAccept=text/plain

Unpaywallhttps://doi.org/10.1016/j.btre.2021.e00681

Europe_PMChttps://europepmc.org/articles/PMC8482554

Europe_PMChttps://europepmc.org/articles/PMC8482554?pdf=render

Fields of Study

0301 basic medicine03 medical and health sciences

Keywords

CountermeasuresCovid-19Sars-cov-2Angiotensin I Converting Enzyme (Ace2) CarboxypeptidaseCytomimeticsShort CommunicationTP248.13-248.65Biotechnology

Sustainable Development Goals

SDG 3: 3. Good health

Related Papers (3)

Clinical Characteristics of Coronavirus Disease 2019 in China

Top 1%

30.3DataRank

New England Journal of Medicine(2020)

co-cited

10.1056/nejmoa2002032

Clinical grade ACE2 as a universal agent to block SARS‐CoV‐2 variants

N/A

0.598DataRank · unranked

EMBO Molecular Medicine(2022)

co-cited

10.15252/emmm.202115230

Development of an aerosol intervention for COVID-19 disease: Tolerability of soluble ACE2 (APN01) administered via nebulizer

N/A

1.0DataRank · unranked

PLoS ONE(2022)

co-cited

10.1371/journal.pone.0271066

ACE2-cytomimetic particles restrict SARS-Cov-2 spike protein binding to cellular targets

FAIR Checklist

Authors (2)

Funding (3 grants)

Open Access

Topics

Annotations (Europe PMC)

Related Papers (3)